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Abstract 
Background: Ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak®) are the newest medicines approved for use 
in the treatment of hepatitis C virus (HCV) and are available in tablet form as an oral combination. Specifically, these 
agents are indicated in the treatment of HCV in patients with genotype 1 infection. Due to the therapeutic impor‑
tance and increased use of Viekira Pak, proper methods for its determination in bulk and pharmaceutical formulations 
must be developed.
Results: The present study describes the development and validation of a simple, rapid, selective and economical 
reverse phase high performance liquid chromatography‑diode array detection (HPLC‑DAD) method for the simulta‑
neous determination of paritaprevir (PAR), ombitasvir (OMB), dasabuvir(DAS) and ritonavir (RIT) in bulk and pharma‑
ceutical preparations. The proposed method was carried out using an RPC18 column (150 × 4.5 mm, 3.5 μ), with a 
mobile phase consisting of 10 mM phosphate buffer (pH 7)and acetonitrile (35:65, v/v) at a flow rate of 1 ml/min and 
a detection wavelength of 254 nm. Sorafenib (SOR) was selected as the internal standard to ensure that the quanti‑
tative performance was high. The method was validated based on its specificity, linearity, limit of detection, limit of 
quantitation, accuracy, precision, robustness and stability. The calibration curves for PAR, DAS, RIT and OMB were linear 
at 2.5–60, 1.25–30, 1.7–40 and 0.42–10 μg/ml, respectively, and all of the correlation coefficients were >0.999.
Conclusions: The proposed method was successfully applied for the determination of ombitasvir/paritaprevir/rito‑
navir/dasabuvirin tablets, without interference from the excipient peaks. Hence, the method can be applied for the 
routine quality control analysis of the studied drugs, either in bulk or dosed forms.
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Background
Approximately 180 million individuals worldwide are 
infected with chronic hepatitis C virus (HCV), and 
500,000 patients die each year from liver disease associ-
ated with hepatitis C, making it the most common blood 
borne pathogen [1–3]. HCV, which belongs to the genus 
Hepacivirus within the family of Flaviviridae, is an envel-
oped virus with a single positive-stranded RNA genome 
[4]. In total, six different genotypes of HCV and multi-
ple subtypes are known, and their distribution varies by 
region. In Saudi Arabia, HCV-genotype 4, followed by 
genotype 1, are the most prevalent [3, 5]. Increasing pro-
tective immune responses in human beings is difficult 
using classic approaches for virus control. As a result, an 
efficient vaccine for the prevention of HCV infection has 
not yet been developed, and the use of antiviral medica-
tions has been the only alternative considered for con-
trolling the HCV epidemic [6]. In the past, a combination 
of peg-interferon (alfa-2a or alfa-2b) and ribavirin was 
the only available treatment regimen for HCV. However, 
these drugs have major disadvantages, such as long treat-
ment courses, suboptimal efficacy, and/or harmful side 
effects. Therefore, the development of a new category 
of more potent and safer antiviral agents was required. 
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Direct-acting antiviral (DAA) therapies, which were 
recently discovered and approved, offer good tolerabil-
ity, short treatment duration, fewer side effects, and high 
cure rates. DAAs work by targeting a variety of stages in 
the HCV life cycle [6–11].
On December 19, 2014, Viekira Pak® (a combina-
tion of ombitasvir (OMB), paritaprevir (PAR) and rito-
navir (RIT) tablets co-packaged with dasabuvir (DAS) 
tablets; Fig. 1) received FDA approval for the treatment 
of chronic HCV genotype 1 infection. Ombitasvir is a 
potent HCV NS5A inhibitor, paritaprevir is a potent 
inhibitor of NS3/4A protease, dasabuvir is a non-nucleo-
side NS5B polymerase inhibitor, and ritonavir is used as a 
pharmacokinetic enhancer for paritaprevir [12, 13]. Sub-
sequently, Technivie® has been approved by the FDA as 
the first DAA for the treatment of chronic HCV genotype 
4 infections without requiring interferon co-administra-
tion. Technivie® includes the same drugs as Viekira Pak® 
with the exception ofdasabuvir [14].
A review of the literature revealed that CE [15, 16], HPLC 
[17–21], UPLC–MS/MS [22–24], LC–MS/MS [25, 26] and 
HPTLC [27, 28] methods have been reported for the analy-
sis of RIT, individually or in combination with other drugs. 
However, a method for the simultaneous determination 
of OMB, PAR, RIT and DAS has not yet been reported. 
Therefore, the purpose of the present work was to develop 
a new method for the simultaneous determination of 
OMB, DAS, PAR and RIT in their bulk and pharmaceutical 
dosage forms. In this report, a simple, rapid, precise, accu-
rate and selective RP-HPLC method was developed and 
validated in accordance with the international conference 
on harmonization (ICH) guidelines [29].
Experimental
Chemicals and reagents
OMB, DAS, PAR, RIT and internal standard SOR were 
purchased from Haoyuan Chemexpress Co., Ltd. (Shang-
hai, China). Samples of Viekirax® and Exviera®tablets 
were obtained as gifts from King Faisal Specialist Hospi-
tal and Research Center (Riyadh, Saudi Arabia) and were 
manufactured by AbbVie Ltd. Acetonitrile (HPLC gradi-
ent-grade) was supplied by Panreac Quimica S.A. (Bar-
celona, Spain). Potassium dihydrogen orthophosphate 
anhydrous was obtained from WINLAB (Leicestershire, 
UK) and sodium hydroxide pellets were supplied by BDH 
Chemicals Ltd. (Poole, UK). Deionized water was used in 
all experiments.
Instrumentation and chromatographic conditions
The HPLC system (Waters, Milford, MA, USA) consisted 
of a waters 1525 binary HPLC pump, a Waters 2998 Pho-
todiode Array Detector, and a Waters 2707 Autosampler. 
The data were acquired and processed using Windows 
XP-based Waters Breeze 2 software. Ultrapure water 
(18  MΩ/cm) was produced by a Milli-Q® Advantage 
A10® Water Purification System (Billerica, MA, USA).
Fig. 1 The chemical structures of the analytes in the present study: a ritonavir; b dasabuvir; c ombitasvir; d paritaprevir
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The chromatographic separations were carried out 
on a reverse phase Waters Symmetry®C18 column 
(150  ×  4.5  mm i.d., particle size 3.5  μm). The mobile 
phase was a mixture of acetonitrile and 10  mM potas-
sium dihydrogen orthophosphate (65:35, v/v; pH 
adjusted to 7 with sodium hydroxide) delivered at a flow 
rate of 1 ml/min. The mobile phase was filtered through 
0.45-µm Whatman®filterpaper and sonicated for 20 min. 
Analysis was performed at ambient temperature, and the 
elution of the compounds was monitored by diode array 
detection (DAD) from 190 to 400  nm. The chromato-
grams were recorded at 254 nm, and the injection volume 
was 20 µl.
Preparation of standard and sample solutions
Preparation of stock solutions
Accurate aliquots of 10 mg of PAR, RIT, OMB and inter-
nal standard SOR were each separately transferred into 
10-ml volumetric flasks, dissolved using acetonitrile and 
diluted up to the mark with the same solvent to obtain 
primary stock solutions (concentration 1000  µg/ml) of 
each drug. The stock solution of DAS was prepared by 
weighing 10 mg of DAS and dissolving it in a very small 
amount of DMSO (10 drops); then, the final volume was 
achieved using acetonitrile to obtain a final concentration 
of 100 µg/ml.
Primary stock solutions of PAR, RIT, OM Band DAS 
were further diluted with the mobile phase to obtain 
working standards in the concentration range of 2.5–60, 
1.25–30, 1.7–40 and 0.42–10  μg/ml for PAR, DAS, RIT 
and OMB, respectively. A standard concentration of 5 µg/
ml SOR (internal standard) was added to the solutions.
Preparation of sample solutions
Ten tablets of Viekirax® (containing 75  mg PAR, 50  mg 
RIT and 12.5  mg OMB) were weighed and finely pow-
dered. A quantity of the powder equivalent to 10 mg of 
PAR was weighed and transferred to a 10-ml volumet-
ric flask. A small amount of acetonitrile was added to 
the flask, and the resulting mixture was sonicated for 
20 min. The final volume was achieved using acetonitrile 
to obtain a final concentration of 1000 µg/ml of PAR. The 
solution was filtered through 0.45-µm filter paper (stock 
solution A).
Ten tablets of Exviera®tablet (containing 250 mg DAS) 
were powdered, and an amount equivalent to 10  mg of 
DAS was accurately weighed into a 10-ml volumetric 
flask and mixed with 10 drops of DMSO. A small amount 
of acetonitrile was then added to this flask. The solution 
was ultra sonicated for 20 min and filled with acetonitrile 
to obtain a final concentration of 1000 µg/ml of DAS. The 
solution was filtered through a 0.45-μm membrane filter 
(stock solution B).
Aliquots of sample stock solutions. A and B were 
further diluted with the mobile phase, and a constant 
amount of 5 μg/ml of SOR was added to each solution to 
obtain final concentrations of 40 μg/ml of PAR, 26.7 μg/
ml of RIT, 6.7 μg/ml of OMB and 15 µg/ml of DAS. The 
resulting solutions were then subjected to analysis by the 
proposed HPLC method.
Results and discussion
Method development and optimization 
of chromatographic conditions
The method was developed based upon the experience 
obtained from the HPLC method previously devel-
oped for the analysis of RIT [17]. The previous experi-
ment was performed using a mobile phase consisting 
of acetonitrile and phosphate buffer (pH 3) at a ratio of 
60:40, v/v. For the separation of RIT from mixtures con-
taining DAS, OMB and PAR, methanol and acetonitrile 
were used as organic modifier, peak symmetry and opti-
mum pressure was obtained by using acetonitrile. Vari-
ous ratios of acetonitrile and phosphate buffer solutions 
and different mobile phase pH values were tested using 
a C18 (150 ×  4.5  mm, 3.5  μm) column, higher acetoni-
trile ratio resulted in shorter retention times of drugs 
Using this mobile phase ratio best results were obtained 
in terms of peak symmetry, selectivity and analysis time 
for drugs and the results are shown in Fig.  2. The pKa 
values of the studied drugs are reported in the literature 
as 2.8 for RIT, 2.5 for OMB, 4.6 for PAR, and 8.2 and 9.2 
for DAS, which has two pKas. Therefore, the pH of the 
mobile phase was adjusted to 7 (Fig. 3). A wavelength of 
254  nm was selected for the simultaneous determina-
tion of HVC drugs with high sensitivity. Moreover, the 
strength of the phosphate buffer solution (10–100  mM) 
was evaluated. Good resolution and reasonable reten-
tion times were observed for all of the drugs when 
acetonitrile:phosphatebuffer (0.01  M) (65: 35, v/v) was 
delivered at a flow rate of 1 ml/min (Fig. 4).
Method validation
Validation of the optimized method was performed 
according to ICH Q2 (R1) guidelines [29]. The follow-
ing validation characteristics were addressed: specificity, 
detection limit, quantitation limit, linearity, precision, 
accuracy and robustness.
System suitability parameters
System suitability tests are used to verify that the resolu-
tion and reproducibility of the system are adequate. Sev-
eral suitability parameters, including the capacity factor, 
selectivity, efficiency, resolution and tailing factor were 
calculated, as shown in Table 1. The peaks obtained were 
sharp and showed clear baseline separation.
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Specificity
The specificity of the proposed HPLC method was 
assessed by comparing the spectrum of each drug in the 
sample with the reference drug spectrum using the diode 
array detector. Chromatograms obtained from standard 
solutions were also compared to those from the sample 
solutions, and interference was not observed in the pres-
ence of formulation excipients, indicating that the speci-
ficity of the method was satisfactory Table 5.
Limit of detection (LOD) and limit of quantitation (LOQ)
The limit of detection and limit of quantitation were 
determined by diluting known concentrations of each 
drug until signal to noise ratios of approximately 3:1 and 
10:1 were obtained, respectively. The LOD and LOQ of 
PAR, DAS, RIT and OMB, which represent the capability 
of the method to detect and quantify low concentrations, 
were 0.0024 and 0.0049  μg/ml, 0.00488 and 0.0098  μg/
ml, 0.0521 and 0.1042  μg/ml, 0.0065 and 0.0130  μg/ml, 
respectively. This result indicates the capability of the 
method to detect and quantify low concentrations. The 
results are summarized in Table 2.
Linearity
The linearity of the response of the detector for each drug 
was determined by plotting the response ratio (ratio of 
the peak area of the drug to that of the internal stand-
ard) versus the drug concentration and calculating the 
corresponding regression equation. The calibration curve 
was linear at concentrations of 2.5–60  µg/ml for PAR, 
Fig. 2 Effect of different ratios of acetonitrile in the mobile phase on the elution of the studied compounds, the order of elution is: paritaprevir 
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Fig. 3 Effect of different ratios of acetonitrile in the mobile phase on 
the elution of the studied compounds, the order of elution is: pari‑
taprevir (PAR), dasabuvir (DAS), ritonavir (RIT), and ombitasvir (OMB)
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1.25–30 µg/ml for DAS, 1.7–40 µg/ml for RIT and 0.42–
10 µg/ml for OMB. For all of the standard solutions, each 
concentration was injected in triplicate to obtain repro-
ducible responses. According to the results of the regres-
sion analysis, which are given in Table 2, the method was 
linear, showing a correlation coefficient of >0.999.
The high values of the correlation coefficients (r) and 
negligible intercepts (a) indicated that the linearity of the 
calibration graphs was acceptable. Sy/x is a measure of 
the extent of deviation between the observed (measured) 
y-values and calculated y-values. For example, low values 
of Sy/x indicate that the point lies close to the regression 
line. The standard deviation (SD) of the intercept (Sa) and 
slope (Sb) were also calculated.
Precision and accuracy
The repeatability of the developed method (intra and 
inter-day precision),which was expressed as the % RSD, 
and the accuracy, which was expressed as the %Er, were 
determined by injecting three different standard solution 
sat each of the low, medium and high concentration lev-
els on the same day for the intra-day study (n = 3) and 
the following two consecutive days for the inter-day stud-
ies (n =  9). As shown in Table 3, the calculated % RSD 
Fig. 4 A typical chromatogram of mixed standard solution: (i) 40 μg/ml PAR; (ii) 15 μg/ml DAS; (iii) 26.7 μg/ml RIT; (vi) 5 μg/ml SOR (IS); (v) 6.7 μg/ml 
OMB
Table 1 System suitability parameters for  the determination of  paritaprevir (PAR), dasabuvir (DAS), ritonavir (RIT), 
and ombitasvir (OMB) using the proposed HPLC method
Analyte Retention time (min) (Rt) Capacity factor (k) Selectivity (α) Resolution (Rs) Tailing (Tf) Efficiency (no. of theoretical plates)
PAR 1.476 1.73 – – 1 2443
DAS 2.835 4.13 2.39 10.62 1.20 8211
RIT 3.499 5.33 1.29 4.25 1 5555
SOR 4.720 7.53 1.41 6.49 1.20 10,085
OMB 6.388 10.53 1.40 6.64 1.20 6632
Table 2 Regression and  statistical parameters for  the 
determination of DAAs using the proposed HPLC method
Ombitasvir (OMB), paritaprevir (PAR), ritonavir (RIT), and dasabuvir (DAS)
a LOD: limit of detection
b LOQ: limit of quantitation
c Sa: standard deviation of intercept
d Sb: standard deviation of slope
e Sy/x:standard deviation of residuals
f F: variance ratio, equals the mean of squares due to regression divided by the 
mean of squares about regression (due to residuals)
PAR DAS RIT OMB
Linearity range 
(µg/ml)
2.5–60 1.25–30 1.7–40 0.42–10
LOD (µg/ml)a 0.0024 0.00488 0.0521 0.0065
LOQ (µg/ml)b 0.0049 0.0098 0.1042 0.0130
Intercept 0.0940 0.0525 0.0057 0.0124
Slope 0.1233 0.2122 0.0144 0.1725
Correlation 
coefficient (r)
0.9995 0.9998 0.9996 0.9997
Sa
c 0.0415 0.0230 0.0031 0.0137
Sb
d 0.0013 0.0015 0.0002 0.0084
Sey/x 0.0682 0.0378 0.0051 0.0016
Ff 8441.8243 20320.4610 9008.7822 11307.0622
Significance F 8.4127E−08 1.4525E−08 7.3875E−08 4.6902E−08
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and % Er were within the acceptable range of values, <2% 
for both % Er and % RSD.
Robustness
The robustness of the method was studied by making 
small but deliberate changes in the chromatographic 
parameters and evaluating the resulting % RSD. The 
optimal injection volume (±5  µl), detection wave-
length (±1  nm), percentage of acetonitrile (±1  ml), 
mobile phase flow (±1 ml/min) and pH of the mobile 
phase (±0.1 unit) were studied by changing a single 
parameter while maintaining the others at a constant 
value. The % RSD is provided in Table  4. Signifi-
cant changes in chromatograms were not observed % 
RSD < 2%, demonstrating the robustness of the devel-
oped method.
Solution stability
The stabilities of both standard and sample solutions 
were examined, and changes in the corresponding chro-
matographs were not observed after 24  h at room tem-
perature and over 3 weeks in a refrigerator (4 °C).
Table 3 Intra-day and inter-day precision and accuracy for the determination of paritaprevir (PAR), dasabuvir (DAS), rito-
navir (RIT), and ombitasvir (OMB) using the proposed HPLC method
a RSD (%): percentage relative standard deviation
b Er (%): percentage relative error
Compound Intraday precision and accuracy (n = 3) Interday precision and accuracy (n = 9)
Standard concentration (μg/ml) Mean % recovery ± SD RSD (%)a Er (%)b Mean % recovery ± SD RSD (%)a Er (%)b
PAR 5 100.53 ± 0.599 0.596 −0.526 99.17 ± 1.227 1.237 0.831
25 99.11 ± 0.133 0.134 0.893 99.22 ± 0.396 0.399 0.781
50 101.39 ± 0.250 0.247 −1.387 101.29 ± 0.232 0.229 −1.288
DAS 3 99.72 ± 0.324 0.326 0.727 98.78 ± 0.567 0.574 1.223
15 100.75 ± 0.143 0.142 −0.752 100.51 ± 0.271 0.270 −0.508
25 100.38 ± 0.17 0.17 −0.384 100.45 ± 0.352 0.350 −0.451
RIT 3.3 101.19 ± 1.183 1.169 −1.191 101.32 ± 0.996 0.983 −1.316
16.7 100.67 ± 0.069 0.068 −0.967 101.54 ± 0.466 0.459 −1.542
33.3 100.92 ± 0.053 0.053 −0.925 101.32 ± 1.164 1.149 −1.315
OMB 0.83 99.23 ± 0.002 0.002 0.768 99.71 ± 1.612 1.617 0.291
4.17 100.85 ± 0.001 0.001 −0.852 100.99 ± 0.312 0.309 −0.995
8.33 101.64 ± 0.006 0.006 −1.637 101.66 ± 0.386 0.379 −1.659
Table 4 Robustness of the proposed HPLC method
All results are average of three determinations
Parameter PAR DAS RIT OMB
RSD % of peak 
areas
k ± SD RSD % of peak 
areas
k ± SD RSD % of peak 
areas





in the mobile 
phase [64, 65 
and 66 ml]
0.290 0.48 ± 0.007 0.177 2.08 ± 0.005 0.446 2.81 ± 0.001 0.335 6.11 ± 0.002
pH of the aque‑
ous phase [6.9, 
7 and 7.1]
0.363 0.53 ± 0.011 0.178 2.03 ± 0.010 0.413 2.73 ± 0.001 0.471 5.85 ± 0.003
Flow rate [0.9, 
1, and 1.1 ml/
min]
0.239 0.53 ± 0.005 0.182 2.12 ± 0.005 0.32 2.87 ± 0.000 0.579 6.25 ± 0.003
Injection volume 
[15, 20, 25 µl]
0.255 0.53 ± 0.024 0.141 1.97 ± 0.026 0.80 2.68 ± 0.01 0.314 5.66 ± 0.007
Detection 
wavelength 
[253, 254 and 
255 nm]
0.403 0.55 ± 0.007 0.089 1.99 ± 0.003 0.394 2.69 ± 0.001 0.580 5.75 ± 0.002
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Analysis of pharmaceutical formulations
The developed HPLC method with DAD was successfully 
applied to analyse the content of PAR, RIT and OMBin 
Viekirax®tablets and DAS in Exviera®tablets. Interfer-
ing peaks were not observed in the chromatogram of the 
marketed formulation, indicating that excipients used 
in the tablets did not interfere with the peaks of inter-
est when the proposed method was employed. The mean 
% recovery of the drug content of the tablets was deter-
mined and was shown to range from 98 to 102%. The 
results are reported in Table 5.
Conclusions
A new method based on isocratic RP-HPLC with DAD 
was developed and validated for the simultaneous deter-
mination of paritaprevir, ombitasvir, ritonavir and dasa-
buvir in bulk and pharmaceutical formulations. The 
reliability assessment showed that the proposed method 
was linear, accurate, precise, reproducible, specific 
and robust. Moreover, all four drugs were successfully 
resolved and quantified within a single analytical run 
with a short operating time (the elution time of the last 
peak was 6.3 min). Therefore, the developed method can 
be used in quality control studies, in which cost and time 
are concerning factors.
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